Jain Rita 4

What Happened
Rita Jain, a director of Avalo Therapeutics, was granted a derivative award for 20,100 shares on 2026-06-02. The Form 4 reports an acquisition price of $0.00, indicating a grant/award rather than an open-market purchase or sale. The award is subject to vesting (see footnote).

Key Details

• Transaction type/code: Grant/Award (A), recorded as a derivative acquisition.
• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04 (filed within the typical two-business-day window).
• Shares involved: 20,100 shares; reported acquisition price: $0.00.
• Vesting: Footnote states the stock option vests 100% on the first anniversary of the grant date, subject to the director’s continued service.
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• No sale or cash exercise reported—this is a grant, not a disposition.

Context
This is a director compensation grant (a derivative award that vests after one year), which is common for non-employee directors and does not by itself indicate buying or selling sentiment. Because the award vests in the future and no immediate sale or exercise occurred, there was no cash flow or change in marketable shares at filing.